Synapse - Solid Tumor Oncology Division

Results (119)

Health-related quality of life with adjuvant nivolumab vs. placebo after radical resection for high-risk muscle-invasive urothelial carcinoma: Results from the phase 3 checkmate 274 trial

Meeting Abstract

Gschwend, J. E.; Bajorin, D.; Galsky, M.; Broughton, E.; Braverman, J.; Koon, H.; Maira-Arce, M.; Hamilton, M.; Shi, L.; Guo, S.; more...
European Urology (2021)

Fulltext@MSK | Save

Neutrophil-to-lymphocyte ratio in unclassified renal cell carcinoma is associated with clinical outcome and varies between genomic subgroups

Meeting Abstract

Marcon, J.; Di Natale, R. G.; Weng, S.; Ghanaat, M.; Silagy, A. W.; Mano, R.; Blum, K. A.; Attalla, K.; Reznik, E.; Carlo, M. I.; more...
European Urology (2021)

Fulltext@MSK | Save

Efficacy and safety of atezolizumab plus bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma in IMmotion150: A randomized phase 2 clinical trial

Journal Article

Powles, T.; Atkins, M. B.; Escudier, B.; Motzer, R. J.; Rini, B. I.; Fong, L.; Joseph, R. W.; Pal, S. K.; Sznol, M.; Hainsworth, J.; more...
European Urology (2021)

Fulltext@MSK | Save

Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: A prespecified subgroup analysis of the IMmotion151 clinical trial

Journal Article

Rini, B. I.; Motzer, R. J.; Powles, T.; McDermott, D. F.; Escudier, B.; Donskov, F.; Hawkins, R.; Bracarda, S.; Bedke, J.; De Giorgi, U.; more...
European Urology (2021)

Fulltext@MSK | Save

Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: Final overall survival analysis of the phase 3 PROTECT trial

Journal Article

Motzer, R. J.; Russo, P.; Haas, N.; Doehn, C.; Donskov, F.; Gross-Goupil, M.; Varlamov, S.; Kopyltsov, E.; Lee, J. L.; Lim, H. Y.; more...
European Urology (2021)

Fulltext@MSK | Save

Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016

Correspondence

Iyer, G.; Bochner, B. H.; Van Allen, E. M.; Solit, D. B.; Rosenberg, J. E.
European Urology (2021)

Fulltext@MSK | Save

Hyperphosphatemia secondary to the selective fibroblast growth factor receptor 1–3 inhibitor infigratinib (BGJ398) is associated with antitumor efficacy in fibroblast growth factor receptor 3–altered advanced/metastatic urothelial carcinoma

Journal Article

Lyou, Y.; Grivas, P.; Rosenberg, J. E.; Hoffman-Censits, J.; Quinn, D. I.; Petrylak, D. P.; Galsky, M.; Vaishampayan, U.; De Giorgi, U.; Gupta, S.; more...
European Urology (2020)

Fulltext@MSK | Save

Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors

Journal Article

Fizazi, K.; Drake, C. G.; Beer, T. M.; Kwon, E. D.; Scher, H. I.; Gerritsen, W. R.; Bossi, A.; van den Eertwegh, A. J. M.; Krainer, M.; Houede, N.; more...
European Urology (2020)

Fulltext@MSK | Save

Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma

Journal Article

Teo, M. Y.; Mota, J. M.; Whiting, K. A.; Li, H. A.; Funt, S. A.; Lee, C. H.; Solit, D. B.; Al-Ahmadie, H.; Milowsky, M. I.; Balar, A. V.; more...
European Urology (2020)

Fulltext@MSK | Save

Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics

Journal Article

Nguyen, B.; Mota, J. M.; Nandakumar, S.; Stopsack, K. H.; Weg, E.; Rathkopf, D.; Morris, M. J.; Scher, H. I.; Kantoff, P. W.; Gopalan, A.; more...
European Urology (2020)

Fulltext@MSK | Save